Healthy Returns: J&J cell therapy gains edge over Bristol Myers rival
J&J's cell therapy is now approved for an earlier line of treatment than a competing drug from Bristol Myers. Meanwhile, a look at Mount Sinai’s approach to AI.
Source: cnbc.com
Page 6 - Johnson Amp News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Johnson Amp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Johnson Amp Today - Breaking & Trending Today
Take some profits if March CPI only matches expectations, investors say
Now may be the time to peel back some winning stocks and boost positions in losing sectors, according to at least two Wall Street investors.
Source: cnbc.com
AstraZeneca tumor drug: AstraZeneca, Daiichi Drug gets broad tumor approval in US
Enhertu, a collaboration between AstraZeneca and Daiichi Sankyo, gains FDA approval for treating HER2-positive solid tumors spread throughout the body, marking a breakthrough in cancer treatment. It's the first antibody drug conjugate with such wide clearance, offering new hope for patients with limited treatment options. AstraZeneca anticipates further growth opportunities.
Source: indiatimes.com
Is Johnson & Johnson Stock A Better Pick Over AbbVie?
AbbVie trades at a higher valuation of 5.5x trailing revenues, compared to 4.6x for JNJ.
Source: forbes.com
5 things to know before the stock market opens Tuesday
5 things to know before the stock market opens Tuesday : Rashtra News #stock #market #opens #Tuesday Here are the most important news, trends and analysis that investors need to start their trading day:1. Futures steady with earnings, rising bond yields in focusTraders work on the floor of the New York Stock Exchange during morning
Source: rashtranews.com